KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Shares Issued (2020 - 2025)

Ginkgo Bioworks Holdings' Shares Issued history spans 6 years, with the latest figure at $19.5 million for Q4 2025.

  • For Q4 2025, Shares Issued rose 23077.38% year-over-year to $19.5 million; the TTM value through Dec 2025 reached $19.5 million, up 23077.38%, while the annual FY2025 figure was $19.5 million, 23077.38% up from the prior year.
  • Shares Issued reached $19.5 million in Q4 2025 per DNA's latest filing, up from $84000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $19.5 million in Q4 2025 to a low of -$16.9 million in Q3 2022.
  • Average Shares Issued over 5 years is $1.2 million, with a median of $27000.0 recorded in 2021.
  • Peak YoY movement for Shares Issued: tumbled 78426.32% in 2021, then soared 141066.67% in 2022.
  • A 5-year view of Shares Issued shows it stood at -$14.9 million in 2021, then skyrocketed by 100.8% to $120000.0 in 2022, then plummeted by 88.33% to $14000.0 in 2023, then surged by 500.0% to $84000.0 in 2024, then skyrocketed by 23077.38% to $19.5 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Shares Issued are $19.5 million (Q4 2025), $84000.0 (Q4 2024), and -$84000.0 (Q3 2024).